文献速递系统性红斑狼疮其他结缔组织病自身炎症与 IgG4 相关病

Teclistamab治疗难治性自身免疫疾病的多中心病例系列

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.
PubMed 文献 · Ann Rheum Dis · 2026-06-19

中位随访5.1个月,11例(61%)达主要临床应答,4例(22%)达轻微至中度应答;但所有患者出现严重低丙种球蛋白血症,5例(28%)发生严重感染,2例晚期心脏受累者死亡。

要点

  • Teclistamab在难治性自身免疫病中诱导治疗-free应答,61%达主要应答。
  • 所有患者发生严重低丙种球蛋白血症,28%出现严重感染。
  • 晚期心脏受累患者出现致命结局,需谨慎选择与监测。

核心结论

  • Teclistamab在难治性自身免疫病中展现诱导无治疗应答的潜力,但感染和晚期心脏受累者致命结局提示需谨慎选择患者和监测。

主要发现

  • 中位既往治疗5种,Teclistamab中位累积剂量6.36 mg/kg,中位随访5.1个月(范围0.8-21.2个月)。
  • 12例(67%)发生22次细胞因子释放综合征(16次1级,6次2级);所有患者出现严重低丙种球蛋白血症,5例(28%)发生严重感染,2例发生炎症性肠病样结肠炎。
  • 2例严重系统性硬化症相关心脏受累患者死亡,1例为心源性猝死,另1例死于弥漫性肺泡出血和心力衰竭。
  • 所有患者均观察到B细胞耗竭,自身抗体水平显著下降;11例(61%)达主要临床应答,4例(22%)达轻微至中度应答,尽管已停用免疫抑制治疗。

临床怎么用

  • 对于难治性自身免疫病患者,Teclistamab可能诱导无治疗应答,但需警惕严重低丙种球蛋白血症和感染风险。
  • 晚期心脏受累患者使用Teclistamab可能出现致命结局,应谨慎选择并加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to evaluate the safety and efficacy of teclistamab, a T cell-redirecting bispecific antibody targeting B-cell maturation antigen, in a case series of severe autoimmune diseases. METHODS: Data were retrospectively collected from patients with treatment-refractory systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIMs), systemic lupus erythematosus (SLE), undifferentiated connective tissue disease (UCTD), or IgG4-related disease (IgG4-RD) who received 1 cycle of teclistamab at 5 European centres. RESULTS: Eighteen patients (72% women, median age 48.5 years, 10 SSc, 4 IIM, 2 SLE, 1 UCTD, and 1 IgG4-RD) with a median of 5 prior therapies and a median cumulative dose of 6.36 mg/kg teclistamab were included. The median follow-up was 5.1 months (range, 0.8-21.2 months). A total of 22 cytokine release syndrome episodes (16 grade 1 and 6 grade 2) occurred in 12 patients (67%). All patients developed severe hypogammaglobulinaemia, and 5 (28%) experienced severe infections. Two patients developed an inflammatory bowel disease-like colitis. Two patients with severe SSc-associated cardiac involvement died, 1 due to sudden cardiac death and the other following diffuse alveolar haemorrhage and heart failure. B-cell depletion was observed in all patients, accompanied by significant reductions in autoantibody levels. Teclistamab was associated with major clinical responses in 11 (61%) and minimal-to-moderate responses in 4 (22%) patients, despite discontinuation of immunosuppressive therapy. CONCLUSIONS: Teclistamab demonstrated the potential to induce treatment-free responses in refractory autoimmune disease, but clinically relevant safety events, including infections and fatal outcomes in patients with advanced cardiac involvement, highlight the need for careful patient selection and monitoring.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Albach FN, Phithak E, Biesen R, et al. Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series. Ann Rheum Dis. 2026. PMID: 42321107. doi:10.1016/j.ard.2026.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。